Close Menu

Published in Nature's early online edition, researchers at Children's Hospital Boston have used stem cells to study why cancer appears less in people with Down syndrome. Following up on previous studies, they found that one gene on chromosome 21, DSCR1, is increased in expression in Down's syndrome tissues and in a mouse model of Down's syndrome. DSCR1, Down's syndrome candidate region-1, encodes a protein that suppresses angiogenesis by the calcineurin pathway.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.